Bill Amendment: IL SB3350 | 2023-2024 | 103rd General Assembly
NOTE: For additional amemendments please see the Bill Drafting List
Bill Title: FENTANYL TEST STRIPS
Status: 2024-08-09 - Public Act . . . . . . . . . 103-0980 [SB3350 Detail]
Download: Illinois-2023-SB3350-Senate_Amendment_001.html
Bill Title: FENTANYL TEST STRIPS
Status: 2024-08-09 - Public Act . . . . . . . . . 103-0980 [SB3350 Detail]
Download: Illinois-2023-SB3350-Senate_Amendment_001.html
| |||||||
| |||||||
1 | AMENDMENT TO SENATE BILL 3350 | ||||||
2 | AMENDMENT NO. ______. Amend Senate Bill 3350 by replacing | ||||||
3 | everything after the enacting clause with the following:
| ||||||
4 | "Section 5. The Substance Use Disorder Act is amended by | ||||||
5 | changing Section 5-23 as follows:
| ||||||
6 | (20 ILCS 301/5-23) | ||||||
7 | Sec. 5-23. Drug Overdose Prevention Program. | ||||||
8 | (a) Reports. | ||||||
9 | (1) The Department may publish annually a report on | ||||||
10 | drug overdose trends statewide that reviews State death | ||||||
11 | rates from available data to ascertain changes in the | ||||||
12 | causes or rates of fatal and nonfatal drug overdose. The | ||||||
13 | report shall also provide information on interventions | ||||||
14 | that would be effective in reducing the rate of fatal or | ||||||
15 | nonfatal drug overdose and on the current substance use | ||||||
16 | disorder treatment capacity within the State. The report |
| |||||||
| |||||||
1 | shall include an analysis of drug overdose information | ||||||
2 | reported to the Department of Public Health pursuant to | ||||||
3 | subsection (e) of Section 3-3013 of the Counties Code, | ||||||
4 | Section 6.14g of the Hospital Licensing Act, and | ||||||
5 | subsection (j) of Section 22-30 of the School Code. | ||||||
6 | (2) The report may include: | ||||||
7 | (A) Trends in drug overdose death rates. | ||||||
8 | (B) Trends in emergency room utilization related | ||||||
9 | to drug overdose and the cost impact of emergency room | ||||||
10 | utilization. | ||||||
11 | (C) Trends in utilization of pre-hospital and | ||||||
12 | emergency services and the cost impact of emergency | ||||||
13 | services utilization. | ||||||
14 | (D) Suggested improvements in data collection. | ||||||
15 | (E) A description of other interventions effective | ||||||
16 | in reducing the rate of fatal or nonfatal drug | ||||||
17 | overdose. | ||||||
18 | (F) A description of efforts undertaken to educate | ||||||
19 | the public about unused medication and about how to | ||||||
20 | properly dispose of unused medication, including the | ||||||
21 | number of registered collection receptacles in this | ||||||
22 | State, mail-back programs, and drug take-back events. | ||||||
23 | (G) An inventory of the State's substance use | ||||||
24 | disorder treatment capacity, including, but not | ||||||
25 | limited to: | ||||||
26 | (i) The number and type of licensed treatment |
| |||||||
| |||||||
1 | programs in each geographic area of the State. | ||||||
2 | (ii) The availability of medication-assisted | ||||||
3 | treatment at each licensed program and which types | ||||||
4 | of medication-assisted treatment are available. | ||||||
5 | (iii) The number of recovery homes that accept | ||||||
6 | individuals using medication-assisted treatment in | ||||||
7 | their recovery. | ||||||
8 | (iv) The number of medical professionals | ||||||
9 | currently authorized to prescribe buprenorphine | ||||||
10 | and the number of individuals who fill | ||||||
11 | prescriptions for that medication at retail | ||||||
12 | pharmacies as prescribed. | ||||||
13 | (v) Any partnerships between programs licensed | ||||||
14 | by the Department and other providers of | ||||||
15 | medication-assisted treatment. | ||||||
16 | (vi) Any challenges in providing | ||||||
17 | medication-assisted treatment reported by programs | ||||||
18 | licensed by the Department and any potential | ||||||
19 | solutions. | ||||||
20 | (b) Programs; drug overdose prevention. | ||||||
21 | (1) The Department may establish a program to provide | ||||||
22 | for the production and publication, in electronic and | ||||||
23 | other formats, of drug overdose prevention, recognition, | ||||||
24 | and response literature. The Department may develop and | ||||||
25 | disseminate curricula for use by professionals, | ||||||
26 | organizations, individuals, or committees interested in |
| |||||||
| |||||||
1 | the prevention of fatal and nonfatal drug overdose, | ||||||
2 | including, but not limited to, drug users, jail and prison | ||||||
3 | personnel, jail and prison inmates, drug treatment | ||||||
4 | professionals, emergency medical personnel, hospital | ||||||
5 | staff, families and associates of drug users, peace | ||||||
6 | officers, firefighters, public safety officers, needle | ||||||
7 | exchange program staff, and other persons. In addition to | ||||||
8 | information regarding drug overdose prevention, | ||||||
9 | recognition, and response, literature produced by the | ||||||
10 | Department shall stress that drug use remains illegal and | ||||||
11 | highly dangerous and that complete abstinence from illegal | ||||||
12 | drug use is the healthiest choice. The literature shall | ||||||
13 | provide information and resources for substance use | ||||||
14 | disorder treatment. | ||||||
15 | The Department may establish or authorize programs for | ||||||
16 | prescribing, dispensing, or distributing opioid | ||||||
17 | antagonists for the treatment of drug overdose and for | ||||||
18 | dispensing and distributing fentanyl test strips to | ||||||
19 | further promote harm reduction efforts and prevent an | ||||||
20 | overdose . Such programs may include the prescribing of | ||||||
21 | opioid antagonists for the treatment of drug overdose to a | ||||||
22 | person who is not at risk of opioid overdose but who, in | ||||||
23 | the judgment of the health care professional, may be in a | ||||||
24 | position to assist another individual during an | ||||||
25 | opioid-related drug overdose and who has received basic | ||||||
26 | instruction on how to administer an opioid antagonist. |
| |||||||
| |||||||
1 | (2) The Department may provide advice to State and | ||||||
2 | local officials on the growing drug overdose crisis, | ||||||
3 | including the prevalence of drug overdose incidents, | ||||||
4 | programs promoting the disposal of unused prescription | ||||||
5 | drugs, trends in drug overdose incidents, and solutions to | ||||||
6 | the drug overdose crisis. | ||||||
7 | (3) The Department may support drug overdose | ||||||
8 | prevention, recognition, and response projects by | ||||||
9 | facilitating the acquisition of opioid antagonist | ||||||
10 | medication approved for opioid overdose reversal, | ||||||
11 | facilitating the acquisition of opioid antagonist | ||||||
12 | medication approved for opioid overdose reversal, | ||||||
13 | providing trainings in overdose prevention best practices, | ||||||
14 | facilitating the acquisition of fentanyl test strips to | ||||||
15 | test for the presence of fentanyl, a fentanyl analog, or a | ||||||
16 | drug adulterant within a controlled substance, connecting | ||||||
17 | programs to medical resources, establishing a statewide | ||||||
18 | standing order for the acquisition of needed medication, | ||||||
19 | establishing learning collaboratives between localities | ||||||
20 | and programs, and assisting programs in navigating any | ||||||
21 | regulatory requirements for establishing or expanding such | ||||||
22 | programs. | ||||||
23 | (4) In supporting best practices in drug overdose | ||||||
24 | prevention programming, the Department may promote the | ||||||
25 | following programmatic elements: | ||||||
26 | (A) Training individuals who currently use drugs |
| |||||||
| |||||||
1 | in the administration of opioid antagonists approved | ||||||
2 | for the reversal of an opioid overdose and in the use | ||||||
3 | of fentanyl test strips to test for the presence of | ||||||
4 | fentanyl, a fentanyl analog, or a drug adulterant | ||||||
5 | within a controlled substance . | ||||||
6 | (B) Directly distributing opioid antagonists | ||||||
7 | approved for the reversal of an opioid overdose rather | ||||||
8 | than providing prescriptions to be filled at a | ||||||
9 | pharmacy. | ||||||
10 | (B-1) Directly distributing fentanyl test strips | ||||||
11 | to test for the presence of fentanyl, a fentanyl | ||||||
12 | analog, or a drug adulterant within a controlled | ||||||
13 | substance. | ||||||
14 | (C) Conducting street and community outreach to | ||||||
15 | work directly with individuals who are using drugs. | ||||||
16 | (D) Employing community health workers or peer | ||||||
17 | recovery specialists who are familiar with the | ||||||
18 | communities served and can provide culturally | ||||||
19 | competent services. | ||||||
20 | (E) Collaborating with other community-based | ||||||
21 | organizations, substance use disorder treatment | ||||||
22 | centers, or other health care providers engaged in | ||||||
23 | treating individuals who are using drugs. | ||||||
24 | (F) Providing linkages for individuals to obtain | ||||||
25 | evidence-based substance use disorder treatment. | ||||||
26 | (G) Engaging individuals exiting jails or prisons |
| |||||||
| |||||||
1 | who are at a high risk of overdose. | ||||||
2 | (H) Providing education and training to | ||||||
3 | community-based organizations who work directly with | ||||||
4 | individuals who are using drugs and those individuals' | ||||||
5 | families and communities. | ||||||
6 | (I) Providing education and training on drug | ||||||
7 | overdose prevention and response to emergency | ||||||
8 | personnel and law enforcement. | ||||||
9 | (J) Informing communities of the important role | ||||||
10 | emergency personnel play in responding to accidental | ||||||
11 | overdose. | ||||||
12 | (K) Producing and distributing targeted mass media | ||||||
13 | materials on drug overdose prevention and response, | ||||||
14 | the potential dangers of leaving unused prescription | ||||||
15 | drugs in the home, and the proper methods for | ||||||
16 | disposing of unused prescription drugs. | ||||||
17 | (c) Grants. | ||||||
18 | (1) The Department may award grants, in accordance | ||||||
19 | with this subsection, to create or support local drug | ||||||
20 | overdose prevention, recognition, and response projects. | ||||||
21 | Local health departments, correctional institutions, | ||||||
22 | hospitals, universities, community-based organizations, | ||||||
23 | and faith-based organizations may apply to the Department | ||||||
24 | for a grant under this subsection at the time and in the | ||||||
25 | manner the Department prescribes. Eligible grant | ||||||
26 | activities include, but are not limited to, purchasing and |
| |||||||
| |||||||
1 | distributing opioid antagonists and fentanyl test strips , | ||||||
2 | hiring peer recovery specialists or other community | ||||||
3 | members to conduct community outreach, and hosting public | ||||||
4 | health fairs or events to distribute opioid antagonists | ||||||
5 | and fentanyl test strips , promote harm reduction | ||||||
6 | activities, and provide linkages to community partners. | ||||||
7 | (2) In awarding grants, the Department shall consider | ||||||
8 | the overall rate of opioid overdose, the rate of increase | ||||||
9 | in opioid overdose, and racial disparities in opioid | ||||||
10 | overdose experienced by the communities to be served by | ||||||
11 | grantees. The Department shall encourage all grant | ||||||
12 | applicants to develop interventions that will be effective | ||||||
13 | and viable in their local areas. | ||||||
14 | (3) (Blank). | ||||||
15 | (3.5) Any hospital licensed under the Hospital | ||||||
16 | Licensing Act or organized under the University of | ||||||
17 | Illinois Hospital Act shall be deemed to have met the | ||||||
18 | standards and requirements set forth in this Section to | ||||||
19 | enroll in the drug overdose prevention program upon | ||||||
20 | completion of the enrollment process except that proof of | ||||||
21 | a standing order and attestation of programmatic | ||||||
22 | requirements shall be waived for enrollment purposes. | ||||||
23 | Reporting mandated by enrollment shall be necessary to | ||||||
24 | carry out or attain eligibility for associated resources | ||||||
25 | under this Section for drug overdose prevention projects | ||||||
26 | operated on the licensed premises of the hospital and |
| |||||||
| |||||||
1 | operated by the hospital or its designated agent. The | ||||||
2 | Department shall streamline hospital enrollment for drug | ||||||
3 | overdose prevention programs by accepting such deemed | ||||||
4 | status under this Section in order to reduce barriers to | ||||||
5 | hospital participation in drug overdose prevention, | ||||||
6 | recognition, or response projects. Any hospital under this | ||||||
7 | paragraph and any other organization deemed eligible by | ||||||
8 | the Department shall be enrolled to receive fentanyl test | ||||||
9 | strips from the Department and distribute fentanyl test | ||||||
10 | strips upon enrollment in the Drug Overdose Prevention | ||||||
11 | Program. | ||||||
12 | (4) In addition to moneys appropriated by the General | ||||||
13 | Assembly, the Department may seek grants from private | ||||||
14 | foundations, the federal government, and other sources to | ||||||
15 | fund the grants under this Section and to fund an | ||||||
16 | evaluation of the programs supported by the grants. | ||||||
17 | (d) Health care professional prescription of opioid | ||||||
18 | antagonists. | ||||||
19 | (1) A health care professional who, acting in good | ||||||
20 | faith, directly or by standing order, prescribes or | ||||||
21 | dispenses an opioid antagonist to: (a) a patient who, in | ||||||
22 | the judgment of the health care professional, is capable | ||||||
23 | of administering the drug in an emergency, or (b) a person | ||||||
24 | who is not at risk of opioid overdose but who, in the | ||||||
25 | judgment of the health care professional, may be in a | ||||||
26 | position to assist another individual during an |
| |||||||
| |||||||
1 | opioid-related drug overdose and who has received basic | ||||||
2 | instruction on how to administer an opioid antagonist | ||||||
3 | shall not, as a result of his or her acts or omissions, be | ||||||
4 | subject to: (i) any disciplinary or other adverse action | ||||||
5 | under the Medical Practice Act of 1987, the Physician | ||||||
6 | Assistant Practice Act of 1987, the Nurse Practice Act, | ||||||
7 | the Pharmacy Practice Act, or any other professional | ||||||
8 | licensing statute or (ii) any criminal liability, except | ||||||
9 | for willful and wanton misconduct. | ||||||
10 | (1.5) Notwithstanding any provision of or requirement | ||||||
11 | otherwise imposed by the Pharmacy Practice Act, the | ||||||
12 | Medical Practice Act of 1987, or any other law or rule, | ||||||
13 | including, but not limited to, any requirement related to | ||||||
14 | labeling, storage, or recordkeeping, a health care | ||||||
15 | professional or other person acting under the direction of | ||||||
16 | a health care professional may, directly or by standing | ||||||
17 | order, obtain, store, and dispense an opioid antagonist to | ||||||
18 | a patient in a facility that includes, but is not limited | ||||||
19 | to, a hospital, a hospital affiliate, or a federally | ||||||
20 | qualified health center if the patient information | ||||||
21 | specified in paragraph (4) of this subsection is provided | ||||||
22 | to the patient. A person acting in accordance with this | ||||||
23 | paragraph shall not, as a result of his or her acts or | ||||||
24 | omissions, be subject to: (i) any disciplinary or other | ||||||
25 | adverse action under the Medical Practice Act of 1987, the | ||||||
26 | Physician Assistant Practice Act of 1987, the Nurse |
| |||||||
| |||||||
1 | Practice Act, the Pharmacy Practice Act, or any other | ||||||
2 | professional licensing statute; or (ii) any criminal | ||||||
3 | liability, except for willful and wanton misconduct. | ||||||
4 | (2) A person who is not otherwise licensed to | ||||||
5 | administer an opioid antagonist may in an emergency | ||||||
6 | administer without fee an opioid antagonist if the person | ||||||
7 | has received the patient information specified in | ||||||
8 | paragraph (4) of this subsection and believes in good | ||||||
9 | faith that another person is experiencing a drug overdose. | ||||||
10 | The person shall not, as a result of his or her acts or | ||||||
11 | omissions, be (i) liable for any violation of the Medical | ||||||
12 | Practice Act of 1987, the Physician Assistant Practice Act | ||||||
13 | of 1987, the Nurse Practice Act, the Pharmacy Practice | ||||||
14 | Act, or any other professional licensing statute, or (ii) | ||||||
15 | subject to any criminal prosecution or civil liability, | ||||||
16 | except for willful and wanton misconduct. | ||||||
17 | (3) A health care professional prescribing an opioid | ||||||
18 | antagonist to a patient shall ensure that the patient | ||||||
19 | receives the patient information specified in paragraph | ||||||
20 | (4) of this subsection. Patient information may be | ||||||
21 | provided by the health care professional or a | ||||||
22 | community-based organization, substance use disorder | ||||||
23 | program, or other organization with which the health care | ||||||
24 | professional establishes a written agreement that includes | ||||||
25 | a description of how the organization will provide patient | ||||||
26 | information, how employees or volunteers providing |
| |||||||
| |||||||
1 | information will be trained, and standards for documenting | ||||||
2 | the provision of patient information to patients. | ||||||
3 | Provision of patient information shall be documented in | ||||||
4 | the patient's medical record or through similar means as | ||||||
5 | determined by agreement between the health care | ||||||
6 | professional and the organization. The Department, in | ||||||
7 | consultation with statewide organizations representing | ||||||
8 | physicians, pharmacists, advanced practice registered | ||||||
9 | nurses, physician assistants, substance use disorder | ||||||
10 | programs, and other interested groups, shall develop and | ||||||
11 | disseminate to health care professionals, community-based | ||||||
12 | organizations, substance use disorder programs, and other | ||||||
13 | organizations training materials in video, electronic, or | ||||||
14 | other formats to facilitate the provision of such patient | ||||||
15 | information. | ||||||
16 | (4) For the purposes of this subsection: | ||||||
17 | "Opioid antagonist" means a drug that binds to opioid | ||||||
18 | receptors and blocks or inhibits the effect of opioids | ||||||
19 | acting on those receptors, including, but not limited to, | ||||||
20 | naloxone hydrochloride or any other similarly acting drug | ||||||
21 | approved by the U.S. Food and Drug Administration. | ||||||
22 | "Health care professional" means a physician licensed | ||||||
23 | to practice medicine in all its branches, a licensed | ||||||
24 | physician assistant with prescriptive authority, a | ||||||
25 | licensed advanced practice registered nurse with | ||||||
26 | prescriptive authority, an advanced practice registered |
| |||||||
| |||||||
1 | nurse or physician assistant who practices in a hospital, | ||||||
2 | hospital affiliate, or ambulatory surgical treatment | ||||||
3 | center and possesses appropriate clinical privileges in | ||||||
4 | accordance with the Nurse Practice Act, or a pharmacist | ||||||
5 | licensed to practice pharmacy under the Pharmacy Practice | ||||||
6 | Act. | ||||||
7 | "Patient" includes a person who is not at risk of | ||||||
8 | opioid overdose but who, in the judgment of the physician, | ||||||
9 | advanced practice registered nurse, or physician | ||||||
10 | assistant, may be in a position to assist another | ||||||
11 | individual during an overdose and who has received patient | ||||||
12 | information as required in paragraph (2) of this | ||||||
13 | subsection on the indications for and administration of an | ||||||
14 | opioid antagonist. | ||||||
15 | "Patient information" includes information provided to | ||||||
16 | the patient on drug overdose prevention and recognition; | ||||||
17 | how to perform rescue breathing and resuscitation; opioid | ||||||
18 | antagonist dosage and administration; the importance of | ||||||
19 | calling 911; care for the overdose victim after | ||||||
20 | administration of the overdose antagonist; and other | ||||||
21 | issues as necessary. | ||||||
22 | (e) Drug overdose response policy. | ||||||
23 | (1) Every State and local government agency that | ||||||
24 | employs a law enforcement officer or fireman as those | ||||||
25 | terms are defined in the Line of Duty Compensation Act | ||||||
26 | must possess opioid antagonists and must establish a |
| |||||||
| |||||||
1 | policy to control the acquisition, storage, | ||||||
2 | transportation, and administration of such opioid | ||||||
3 | antagonists and to provide training in the administration | ||||||
4 | of opioid antagonists. A State or local government agency | ||||||
5 | that employs a fireman as defined in the Line of Duty | ||||||
6 | Compensation Act but does not respond to emergency medical | ||||||
7 | calls or provide medical services shall be exempt from | ||||||
8 | this subsection. | ||||||
9 | (2) Every publicly or privately owned ambulance, | ||||||
10 | special emergency medical services vehicle, non-transport | ||||||
11 | vehicle, or ambulance assist vehicle, as described in the | ||||||
12 | Emergency Medical Services (EMS) Systems Act, that | ||||||
13 | responds to requests for emergency services or transports | ||||||
14 | patients between hospitals in emergency situations must | ||||||
15 | possess opioid antagonists. | ||||||
16 | (3) Entities that are required under paragraphs (1) | ||||||
17 | and (2) to possess opioid antagonists may also apply to | ||||||
18 | the Department for a grant to fund the acquisition of | ||||||
19 | opioid antagonists and training programs on the | ||||||
20 | administration of opioid antagonists. | ||||||
21 | (Source: P.A. 101-356, eff. 8-9-19; 102-598, eff. 1-1-22 .)
| ||||||
22 | Section 10. The Overdose Prevention and Harm Reduction Act | ||||||
23 | is amended by changing Section 5 as follows:
| ||||||
24 | (410 ILCS 710/5) |
| |||||||
| |||||||
1 | Sec. 5. Needle and hypodermic syringe access program. | ||||||
2 | (a) Any governmental or nongovernmental organization, | ||||||
3 | including a local health department, community-based | ||||||
4 | organization, or a person or entity, that promotes | ||||||
5 | scientifically proven ways of mitigating health risks | ||||||
6 | associated with drug use and other high-risk behaviors may | ||||||
7 | establish and operate a needle and hypodermic syringe access | ||||||
8 | program. The objective of the program shall be accomplishing | ||||||
9 | all of the following: | ||||||
10 | (1) reducing the spread of HIV, AIDS, viral hepatitis, | ||||||
11 | and other bloodborne diseases; | ||||||
12 | (2) reducing the potential for needle stick injuries | ||||||
13 | from discarded contaminated equipment; and | ||||||
14 | (3) facilitating connections or linkages to | ||||||
15 | evidence-based treatment. | ||||||
16 | (b) Programs established under this Act shall provide all | ||||||
17 | of the following: | ||||||
18 | (1) Disposal of used needles and hypodermic syringes. | ||||||
19 | (2) Needles, hypodermic syringes, and other safer drug | ||||||
20 | consumption supplies, at no cost and in quantities | ||||||
21 | sufficient to ensure that needles, hypodermic syringes, or | ||||||
22 | other supplies are not shared or reused. | ||||||
23 | (3) Educational materials or training on: | ||||||
24 | (A) overdose prevention and intervention; and | ||||||
25 | (B) the prevention of HIV, AIDS, viral hepatitis, | ||||||
26 | and other common bloodborne diseases resulting from |
| |||||||
| |||||||
1 | shared drug consumption equipment and supplies. | ||||||
2 | (4) Access to opioid antagonists approved for the | ||||||
3 | reversal of an opioid overdose, or referrals to programs | ||||||
4 | that provide access to opioid antagonists approved for the | ||||||
5 | reversal of an opioid overdose. | ||||||
6 | (5) Linkages to needed services, including mental | ||||||
7 | health treatment, housing programs, substance use disorder | ||||||
8 | treatment, and other relevant community services. | ||||||
9 | (6) Individual consultations from a trained employee | ||||||
10 | tailored to individual needs. | ||||||
11 | (7) If feasible, a hygienic, separate space for | ||||||
12 | individuals who need to administer a prescribed injectable | ||||||
13 | medication that can also be used as a quiet space to gather | ||||||
14 | composure in the event of an adverse on-site incident, | ||||||
15 | such as a nonfatal overdose. | ||||||
16 | (8) If feasible, access to on-site drug adulterant | ||||||
17 | testing supplies. | ||||||
18 | (9) If feasible, access to fentanyl test strips to | ||||||
19 | test for the presence of fentanyl, a fentanyl analog, or a | ||||||
20 | drug adulterant within a controlled substance. | ||||||
21 | (c) Notwithstanding any provision of the Illinois | ||||||
22 | Controlled Substances Act, the Drug Paraphernalia Control Act, | ||||||
23 | or any other law, no employee or volunteer of or participant in | ||||||
24 | a program established under this Act shall be charged with or | ||||||
25 | prosecuted for possession of any of the following: | ||||||
26 | (1) Needles, hypodermic syringes, or other drug |
| |||||||
| |||||||
1 | consumption paraphernalia obtained from or returned, | ||||||
2 | directly or indirectly, to a program established under | ||||||
3 | this Act. | ||||||
4 | (2) Residual amounts of a controlled substance | ||||||
5 | contained in used needles, used hypodermic syringes, or | ||||||
6 | other used drug consumption paraphernalia obtained from or | ||||||
7 | returned, directly or indirectly, to a program established | ||||||
8 | under this Act. | ||||||
9 | (3) Drug adulterant testing supplies obtained from or | ||||||
10 | returned, directly or indirectly, to a program established | ||||||
11 | under this Act or a pharmacy, hospital, clinic, or other | ||||||
12 | health care facility or medical office dispensing drug | ||||||
13 | adulterant testing supplies in accordance with Section 10. | ||||||
14 | This paragraph also applies to any employee or customer of | ||||||
15 | a pharmacy, hospital, clinic, or other health care | ||||||
16 | facility or medical office dispensing drug adulterant | ||||||
17 | testing supplies in accordance with Section 10. | ||||||
18 | (4) Any residual amounts of controlled substances used | ||||||
19 | in the course of testing the controlled substance to | ||||||
20 | determine the chemical composition and potential threat of | ||||||
21 | the substances obtained for consumption that are obtained | ||||||
22 | from or returned, directly or indirectly, to a program | ||||||
23 | established under this Act. This paragraph also applies to | ||||||
24 | any person using drug adulterant testing supplies procured | ||||||
25 | in accordance with Section 10 of this Act. | ||||||
26 | In addition to any other applicable immunity or limitation |
| |||||||
| |||||||